1. Home
  2. ARRY vs MLYS Comparison

ARRY vs MLYS Comparison

Compare ARRY & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARRY
  • MLYS
  • Stock Information
  • Founded
  • ARRY 1989
  • MLYS 2019
  • Country
  • ARRY United States
  • MLYS United States
  • Employees
  • ARRY N/A
  • MLYS N/A
  • Industry
  • ARRY Semiconductors
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARRY Technology
  • MLYS Health Care
  • Exchange
  • ARRY Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • ARRY 858.3M
  • MLYS 890.6M
  • IPO Year
  • ARRY 2020
  • MLYS 2023
  • Fundamental
  • Price
  • ARRY $7.62
  • MLYS $14.52
  • Analyst Decision
  • ARRY Buy
  • MLYS Strong Buy
  • Analyst Count
  • ARRY 18
  • MLYS 4
  • Target Price
  • ARRY $9.21
  • MLYS $27.00
  • AVG Volume (30 Days)
  • ARRY 7.6M
  • MLYS 785.9K
  • Earning Date
  • ARRY 08-07-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • ARRY N/A
  • MLYS N/A
  • EPS Growth
  • ARRY N/A
  • MLYS N/A
  • EPS
  • ARRY N/A
  • MLYS N/A
  • Revenue
  • ARRY $1,171,244,000.00
  • MLYS N/A
  • Revenue This Year
  • ARRY $25.90
  • MLYS N/A
  • Revenue Next Year
  • ARRY $14.14
  • MLYS N/A
  • P/E Ratio
  • ARRY N/A
  • MLYS N/A
  • Revenue Growth
  • ARRY 6.36
  • MLYS N/A
  • 52 Week Low
  • ARRY $3.76
  • MLYS $8.24
  • 52 Week High
  • ARRY $8.87
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • ARRY 64.77
  • MLYS 57.42
  • Support Level
  • ARRY $5.39
  • MLYS $12.59
  • Resistance Level
  • ARRY $6.36
  • MLYS $13.70
  • Average True Range (ATR)
  • ARRY 0.54
  • MLYS 0.75
  • MACD
  • ARRY 0.10
  • MLYS 0.11
  • Stochastic Oscillator
  • ARRY 89.92
  • MLYS 75.39

About ARRY Array Technologies Inc.

Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers referred to as a single-axis tracker that move solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil and Rest of the World with the United States deriving the majority of the revenue.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: